Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Tetrahydrouridine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Aug 2017 Planned initiation date changed from 18 Aug 2017 to 21 Aug 2017.
- 12 Aug 2017 Planned initiation date changed from 16 Aug 2017 to 18 Aug 2017.
- 10 Aug 2017 Planned initiation date changed from 15 Aug 2017 to 16 Aug 2017.